{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,1]],"date-time":"2026-10-01T07:32:00Z","timestamp":1790839920669,"version":"4.1.0"},"reference-count":26,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2006,2,1]],"date-time":"2006-02-01T00:00:00Z","timestamp":1138752000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["International Journal of Antimicrobial Agents"],"published-print":{"date-parts":[[2006,2]]},"DOI":"10.1016\/j.ijantimicag.2005.10.014","type":"journal-article","created":{"date-parts":[[2006,1,19]],"date-time":"2006-01-19T19:07:22Z","timestamp":1137697642000},"page":"174-177","source":"Crossref","is-referenced-by-count":33,"title":["In vitro interactions of anidulafungin with azole antifungals, amphotericin B and 5-fluorocytosine against Candida species"],"prefix":"10.1016","volume":"27","author":[{"given":"James A.","family":"Karlowsky","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daryl J.","family":"Hoban","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"George G.","family":"Zhanel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Beth P.","family":"Goldstein","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ijantimicag.2005.10.014_bib1","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1086\/421946","article-title":"Nosocomial bloodstream infections in US hospitals: analysis of 24,179 cases from a prospective nationwide surveillance study","volume":"39","author":"Wisplinghoff","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib2","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1086\/378745","article-title":"Attributable mortality of nosocomial candidemia, revisited","volume":"37","author":"Gudlaugsson","year":"2003","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib3","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1128\/JCM.40.4.1298-1302.2002","article-title":"Epidemiology of candidemia: 3-year results from the emerging infections and the epidemiology of Iowa organisms study","volume":"40","author":"Diekema","year":"2002","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib4","doi-asserted-by":"crossref","first-page":"3149","DOI":"10.1128\/AAC.47.10.3149-3154.2003","article-title":"Antifungal susceptibility survey of 2,000 bloodstream Candida isolates in the United States","volume":"47","author":"Ostrosky-Zeichner","year":"2003","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib5","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1517\/13543784.3.8.821","article-title":"The echinocandins: antifungals targeted to the fungal cell wall","volume":"3","author":"Debono","year":"1994","journal-title":"Expert Opin Investig Drugs"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib6","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1128\/AAC.41.4.763","article-title":"In vitro susceptibilities of clinical yeast isolates to a new echinocandin derivative, LY303366, and other antifungal agents","volume":"41","author":"Pfaller","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib7","doi-asserted-by":"crossref","first-page":"1156","DOI":"10.1128\/AAC.41.5.1156","article-title":"In vitro activity of a new echinocandin, LY303366, compared with those of amphotericin B and fluconazole against clinical yeast isolates","volume":"41","author":"Uzun","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib8","doi-asserted-by":"crossref","first-page":"863","DOI":"10.1128\/AAC.41.4.863","article-title":"In vitro activity of a new semisynthetic echinocandin, LY303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species","volume":"41","author":"Zhanel","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib9","doi-asserted-by":"crossref","first-page":"2950","DOI":"10.1128\/JCM.36.10.2950-2956.1998","article-title":"Comparison of in vitro activities of the new triazole SCH56592 and the echinocandins MK-0991 (L-743,872) and LY303366 against opportunistic filamentous and dimorphic fungi and yeasts","volume":"36","author":"Espinel-Ingroff","year":"1998","journal-title":"J Clin Microbiol"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib10","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/S0732-8893(98)00050-9","article-title":"Activity of MK-0991 (L-743,872), a new echinocandin, compared with those of LY303366 and four other antifungal agents tested against blood stream isolates of Candida spp","volume":"32","author":"Marco","year":"1998","journal-title":"Diagn Microbiol Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib11","doi-asserted-by":"crossref","first-page":"697","DOI":"10.1093\/jac\/44.5.697","article-title":"In-vitro activity of voriconazole (UK-109,496) LY303366 and other antifungal agents against oral Candida spp. isolates from HIV-infected patients","volume":"44","author":"Chavez","year":"1999","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib12","doi-asserted-by":"crossref","first-page":"475","DOI":"10.1093\/jac\/46.3.475","article-title":"Susceptibility of fluconazole-resistant clinical isolates of Candida spp. to echinocandin LY303366, itraconazole and amphotericin B","volume":"46","author":"Cuenca-Estrella","year":"2000","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib13","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1159\/000007320","article-title":"In vitro susceptibility of Candida dubliniensis to current and new antifungal agents","volume":"46","author":"Quindos","year":"2000","journal-title":"Chemotherapy"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib14","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1046\/j.1469-0691.2001.00158.x","article-title":"In vitro activity of a new echinocandin, LY303366, and comparison with fluconazole, flucytosine and amphotericin B against Candida species","volume":"7","author":"Moore","year":"2001","journal-title":"Clin Microbiol Infect"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib15","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/jac\/dkg018","article-title":"Antifungal activity of the echinocandin anidulafungin (VER002, LY-303366) against yeast pathogens: a comparative study with M27-A microdilution method","volume":"51","author":"Arevalo","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib16","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1093\/jac\/dkh504","article-title":"Initial results from a longitudinal international surveillance programme for anidulafungin (2003)","volume":"54","author":"Messer","year":"2004","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib17","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1128\/AAC.45.2.471-479.2001","article-title":"Dosage-dependent antifungal efficacy of V-echinocandin (LY303366) against experimental fluconazole-resistant oropharyngeal and esophageal candidiasis","volume":"45","author":"Petraitis","year":"2001","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib18","doi-asserted-by":"crossref","first-page":"2148","DOI":"10.1128\/AAC.43.9.2148","article-title":"Antifungal activity of LY303366, a novel echinocandin B, in experimental disseminated candidiasis in rabbits","volume":"43","author":"Petraitiene","year":"1999","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib19","unstructured":"Gumbo T, Louie A, Liu W, Deziel M, Drusano MF, Drusano GL. Relative efficacies of anidulafungin, fluconazole, and amphotericin B for treatment of disseminated Candida glabrata in neutropenic mice. In: 43rd Interscience Conference on Antimicrobial Agents and Chemotherapy; Chicago; 14\u201317 September 2003."},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib20","doi-asserted-by":"crossref","first-page":"2021","DOI":"10.1128\/AAC.48.6.2021-2024.2004","article-title":"Phase 2, randomized, dose-ranging study evaluating the safety and efficacy of anidulafungin in invasive candidiasis and candidemia","volume":"48","author":"Krause","year":"2004","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib21","doi-asserted-by":"crossref","first-page":"770","DOI":"10.1086\/423378","article-title":"A randomized, double-blind trial of anidulafungin versus fluconazole for the treatment of esophageal candidiasis","volume":"39","author":"Krause","year":"2004","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib22","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1300\/J100v03n04_04","article-title":"Combination systemic antifungal therapy for cryptococcosis, candidiasis and aspergillosis","volume":"3","author":"Lewis","year":"1999","journal-title":"J Infect Dis Pharmacother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib23","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1093\/jac\/49.2.345","article-title":"Comparison of Etest, chequerboard dilution and time\u2013kill studies for the detection of synergy or antagonism between antifungal agents tested against Candida species","volume":"49","author":"Lewis","year":"2002","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib24","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1128\/AAC.41.11.2326","article-title":"In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)","volume":"41","author":"Bartizal","year":"1997","journal-title":"Antimicrob Agents Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib25","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1093\/jac\/dkg230","article-title":"Efficacy of caspofungin combined with amphotericin B against azole-resistant Candida albicans","volume":"51","author":"Hossain","year":"2003","journal-title":"J Antimicrob Chemother"},{"key":"10.1016\/j.ijantimicag.2005.10.014_bib26","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/S0732-8893(02)00361-9","article-title":"Antifungal activities of fluconazole, caspofungin (MK0991), and anidulafungin (LY303366) alone and in combination against Candida spp. and Cryptococcus neoformans via time\u2013kill methods","volume":"43","author":"Roling","year":"2002","journal-title":"Diagn Microbiol Infect Dis"}],"container-title":["International Journal of Antimicrobial Agents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905003468?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0924857905003468?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,4,12]],"date-time":"2020-04-12T05:32:49Z","timestamp":1586669569000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0924857905003468"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006,2]]},"references-count":26,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2006,2]]}},"alternative-id":["S0924857905003468"],"URL":"https:\/\/doi.org\/10.1016\/j.ijantimicag.2005.10.014","relation":{},"ISSN":["0924-8579"],"issn-type":[{"value":"0924-8579","type":"print"}],"subject":[],"published":{"date-parts":[[2006,2]]}}}